These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18769157)

  • 1. Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.
    Pashtan I; Tsutsumi S; Wang S; Xu W; Neckers L
    Cell Cycle; 2008 Sep; 7(18):2936-41. PubMed ID: 18769157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
    Wang S; Pashtan I; Tsutsumi S; Xu W; Neckers L
    Cell Cycle; 2009 Jul; 8(13):2050-6. PubMed ID: 19502802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
    Ou WB; Hubert C; Corson JM; Bueno R; Flynn DL; Sugarbaker DJ; Fletcher JA
    Neoplasia; 2011 Jan; 13(1):12-22. PubMed ID: 21245936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
    Mueller KL; Hunter LA; Ethier SP; Boerner JL
    Cancer Res; 2008 May; 68(9):3314-22. PubMed ID: 18451158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
    Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
    Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone.
    Yano A; Tsutsumi S; Soga S; Lee MJ; Trepel J; Osada H; Neckers L
    Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15541-6. PubMed ID: 18840695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
    Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis.
    Li X; Luo R; Jiang R; Meng X; Wu X; Zhang S; Hua W
    BMC Cardiovasc Disord; 2013 Feb; 13():8. PubMed ID: 23425388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Jiao Y; Ou W; Meng F; Zhou H; Wang A
    Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
    Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
    Breinig M; Mayer P; Harjung A; Goeppert B; Malz M; Penzel R; Neumann O; Hartmann A; Dienemann H; Giaccone G; Schirmacher P; Kern MA; Chiosis G; Rieker RJ
    Clin Cancer Res; 2011 Apr; 17(8):2237-49. PubMed ID: 21372220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
    Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation.
    Koga F; Xu W; Karpova TS; McNally JG; Baron R; Neckers L
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11318-22. PubMed ID: 16844778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
    Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.